The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer

Cancer

Volumn 120, Issue 15, 2014, Pages 2299-2307

  Zhao, Mingchuan ^a   Zhang, Yishi ^a   Cai, Weijing ^a   Li, Jiayu ^a   Zhou, Fei ^a   Cheng, Ningning ^a   Ren, Ruixin ^a   Zhao, Chao ^a   Li, Xuefei ^a   Ren, Shengxiang ^a   Zhou, Caicun ^a   Hirsch, Fred R ^b  

^a TONGJI UNIVERSITY   (China)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

B cell chronic lymphocytic leukemia lymphoma (Bcl 2) like 11; Bim; EGFR; epidermal growth factor receptor; non small cell lung cancer; polymorphism; tyrosine kinase inhibitors

Indexed keywords

BIM PROTEIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; EGFR PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BIM GENE; CHINESE; DNA EXTRACTION; DNA SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE DELETION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; VERY ELDERLY; WILD TYPE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DELETION; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84904767150     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28725     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
3. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
5. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12: 735-742.
6. Chen G, Feng J, Zhou C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol. 2013; 24: 1615-1622.
7. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104: 20932-20937.
8. Ciardiello F, Tortora G,. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358: 1160-1174.
9. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786-792.
10. Huang CP, Tsai MF, Chang TH, et al. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 2013; 328: 144-151.
11. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008; 9: 962-972.
12. Tiseo M, Capelletti M, De Palma G, et al. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J Thorac Oncol. 2008; 3: 1104-1111.
13. Ishikawa N, Daigo Y, Takano A, et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 2005; 65: 9176-9184.
14. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005; 17: 393-403.
15. Gillings AS, Balmanno K, Wiggins CM, Johnson M, Cook SJ,. Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J. 2009; 276: 6050-6062.
16. Gong YX, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 2007; 4: 1655-1668.
17. Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012; 18: 521-528.
18. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010; 28: 357-360.
19. Belloc F, Moreau-Gaudry F, Uhalde M, et al. Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. Cancer Biol Ther. 2007; 6: 912-919.
20. San Jose-Eneriz E, Agirre X, Jimenez-Velasco A, et al. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 2009; 45: 1877-1889.
21. Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K,. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Oncogene. 2011; 30: 4097-4106.
22. Takezawa K, Okamoto I, Nishio K, Janne PA, Nakagawa K,. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res. 2011; 17: 2140-2148.
23. Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA,. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim [serial online]. PLoS One. 2010; 5: e13026.
24. Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007; 4: 1669-1679; discussion 1680.
25. Katagiri S, Umezu T, Ohyashiki JH, Ohyashiki K,. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients. Br J Haematol. 2013; 160: 269-271.
26. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009; 15: 5267-5273.
27. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361: 958-967.
28. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12 (3 pt 1): 839-844.
29. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-128.
30. Lee JK, Shin JY, Kim S, et al. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol. 2013; 24: 2080-2087.
31. Nakagawa T, Takeuchi S, Yamada T, et al. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res. 2013; 73: 2428-2434.